Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
761 to 780 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Characterization of antigenic proteins of the Taenia solium postoncospheral form. | Mol Biochem Parasitol | 2024 | 38705360 | PubTator, text mining | PubMed |
| Single-sEV profiling identifies the TACSTD2 + sEV subpopulation as a factor of tumor susceptibility in the elderly. | J Nanobiotechnology | 2024 | 38698420 | PubTator, text mining | PubMed |
| BRAF mutation, selected miRNAs and genes expression in primary papillary thyroid carcinomas and local lymph node metastases. | Pathol Res Pract | 2024 | 38696857 | PubTator, text mining | PubMed |
| TROP2 promotes PINK1-mediated mitophagy and apoptosis to accelerate the progression of senile chronic obstructive pulmonary disease by up-regulating DRP1 expression. | Exp Gerontol | 2024 | 38685507 | PubTator, text mining | PubMed |
| Cis-regulatory control of transcriptional timing and noise in response to estrogen. | Cell Genom | 2024 | 38663407 | PubTator, text mining | PubMed |
| A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers. | NPJ Precis Oncol | 2024 | 38654141 | PubTator, text mining | PubMed |
| Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. | J Clin Oncol | 2024 | 38652877 | PubTator, text mining | PubMed |
| Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies. | bioRxiv | 2024 | 38645034 | PubTator, text mining | PubMed |
| New therapeutic target molecules for gastric and gastroesophageal junction cancer. | Int J Clin Oncol | 2024 | 38630383 | PubTator, text mining | PubMed |
| Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer. | Clin Transl Med | 2024 | 38629624 | PubTator, text mining | PubMed |
| TROP2 is highly expressed in triple-negative breast cancer CTCs and is a potential marker for epithelial mesenchymal CTCs. | Mol Ther Oncol | 2024 | 38596285 | PubTator, text mining | PubMed |
| Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. | Clin Pharmacokinet | 2024 | 38578394 | PubTator, text mining | PubMed |
| ImmunoPET imaging of Trop2 in patients with solid tumours. | EMBO Mol Med | 2024 | 38565806 | PubTator, text mining | PubMed |
| Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer. | Heliyon | 2024 | 38560142 | PubTator, text mining | PubMed |
| Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. | Cell | 2024 | 38552610 | PubTator, text mining | PubMed |
| Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. | Cancer Treat Rev | 2024 | 38502995 | PubTator, text mining | PubMed |
| Re: Assessment of PD-L1, TROP2, and NECTIN-4 Expression in Penile Squamous Cell Carcinoma. | Eur Urol | 2024 | 38485575 | PubTator, text mining | PubMed |
| TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma. | Pathologica | 2024 | 38482675 | PubTator, text mining | PubMed |
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab. | Breast Cancer Res Treat | 2024 | 38456970 | PubTator, text mining | PubMed |
| Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer. | Target Oncol | 2024 | 38446351 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=39